Detalle Publicación

Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial

Autores: Ledermann, Jonathan A.; Embleton, Andrew C.; Raja, Fharat; Perren, Timothy J.; Jayson, Gordon C.; Rustin, Gordon J. S.; Kaye, Stan B.; Hirte, Hal; Eisenhauer, Elizabeth; Vaughan, Michelle; Friedlander, Michael; González Martín, Antonio; Stark, Daniel; Clark, Elizabeth; Farrelly, Laura; Swart, Ann Marie; Cook, Adrian; Kaplan, Richard S.; Parmar, Mahesh K. B.; ICON6 Collaborators
Título de la revista: LANCET
ISSN: 1474-547X
Volumen: 387
Número: 10023
Páginas: 1066-1074
Fecha de publicación: 2016
Resumen:
Cediranib, when given orally with chemotherapy and continued as maintenance, yielded a meaningful improvement [corrected] in progression-free survival in women with recurrent platinum-sensitive ovarian cancer, albeit with added toxic effects. The positive results in ICON6 could provide women with a new therapeutic option for recurrent ovarian cancer. Assessment of the secondary endpoint of overall survival will need longer follow-up.
DOI: https://doi.org/10.1016/S0140-6736(15)01167-8.
Impacto:
Google Scholar